Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

Returns on capital

Aldeyra Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-76.5%

avg -62.0%

ROIC

-59.0%

avg -54.2%

ROA

-47.0%

avg -47.2%

Analysis

ROA is currently the strongest return metric at -47.0% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Todd C. Brady

Chief Executive Officer, President & DirectorUSD 903K541.72M2.85%

Michael Alfieri

Head of Finance and Principal Financial & Accounting OfficerUSD 243.99K617.50K0.01%

Laura Nichols

Operations Manager————

Adam Lazorchak

Director of Translational Sciences & Non-Clinical Development————

David Burke

Head of Investor Relations————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$523,550.00

Sells

0

$0.00

Net Transaction Value

+$523,550.00

Net buying

Most Active

Brady Todd C

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 3, 26

Brady Todd C

Direct

Buy$418.5K
Mar 19, 26

DOUGLAS RICHARD

Direct

Buy$98K
Mar 18, 26

Alfieri Michael

Direct

Buy$7.1K

Summary

Insiders reported 3 buys worth $523,550.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $523,550.00. Brady Todd C was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Aldeyra Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ALDX's management, answered from reported figures.

Who manages ALDX?

Aldeyra Therapeutics, Inc. (ALDX) lists 5 active executives. The top listed executive is Laura Nichols, Operations Manager.

Are ALDX insiders buying or selling?

Recent insider activity shows net buying of $73.32M.